Home  >  TopNews
Eppen_epTIPS_Dec2025
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

Odisha govt convenes ‘Pharma summit’ on November 20 in Bhubaneswar to attract investors

Peethaambaran Kunnathoor, Chennai
Monday, November 10, 2025, 08:00 Hrs  [IST]

The Government of Odisha has issued a comprehensive and robust invitation to investors from across the country to participate in the upcoming ‘Odisha Pharma Summit’ scheduled for November 20 in Bhubaneswar.

Highlighting the state as the ‘Next Big Opportunity in Pharmaceuticals and Med-Tech’, the summit is positioned as a dedicated Investors' Meet. The state is making a bold pitch as India's fastest-growing investment destination for the pharmaceuticals, medical devices, and allied healthcare sectors, setting an ambitious investment target of Rs. 50,000 crore for the sector.

The initiative is directly championed by Chief Minister of Odisha, Mohan Charan Majhi, and is aligned with the national vision led by Prime Minister, Narendra Modi. This strategic push is rooted in Odisha’s determination to transform the state into the pharmaceutical powerhouse of eastern India within the next few years. The plan aims at significant economic diversification and employment generation, with a goal of creating over 2.5 lakh jobs in the sector. The Industrial Promotion and Investment Corporation of Odisha Limited (IPICOL) is leading the charge, with the Federation of Indian Chambers of Commerce & Industry (FICCI) serving as the National Industry Partner for the event.

The core attraction for investors is the state’s newly unveiled ‘Odisha Pharmaceuticals and Medical Devices Policy’, which promises a regime of Best-in-class Incentives. This new policy marks a significant upgrade over the state's previous 2016 policy and is designed to tackle the current limited presence of the sector. The framework is a clear signal of the government's resolve to create an ultra-conducive environment for both large-scale domestic and international pharmaceutical manufacturing, addressing the challenge of transforming Odisha into a major pharmaceutical player.

Under the new policy, major financial sops are being offered to substantially reduce the cost of establishment for investors. The most notable incentives include a generous 30 per cent capital investment subsidy on the cost of plant and machinery (P&M) with no upper cap on the quantum of subsidy. To streamline the process for major projects, the state has granted 100 per cent exempted stamp duty on concessional industrial land rates, effectively lowering the barrier to entry for setting up large manufacturing units and accelerating project timelines.

Beyond capital investment, the state is offering exceptional operational and workforce support. Manufacturing units will benefit from utility subsidies, including a Rs. 2 per unit power subsidy and 100 per cent electricity duty reimbursement.

In a unique move to foster a skilled local workforce, the government will provide a monthly subsidy for five years to Odisha-domicile employees in biotech technical roles, Rs.15,000 per month for female employees and Rs. 12,500 per month for male employees, alongside ESI/EPF reimbursement, showcasing a focus on inclusive growth.

The promise of a Ready-to-Move Industrial Ecosystem reinforces Odisha’s recognition as a top achiever in Ease of Doing Business with a fast-tracked approval process. The state boasts a Robust Industrial Infrastructure and Dedicated Industrial Parks and Special Economic Zones (SEZs) earmarked for pharma manufacturing, including the Bhubaneswar Biotechnology Park, Tata SEZ at Gopalpur, and PCPIR, Paradeep.

Notably, the Tata SEZ at Gopalpur has already received in-principle approval for a Bulk Drug Park, complete with facilities like a Common Effluent Treatment Plant (CETP), and offers Land Parcels Readily Available near the port with pre-existing environment clearance.

Investors are specifically urged to seize emerging opportunities across the pharmaceutical value chain, including formulations, APIs (active pharmaceutical ingredients), medical devices, disposables, biotechnology, and pharma ancillary (such as packaging, vials, and films). With its strategic location, abundant skilled workforce, and reliable utilities completing the investment pitch, the government’s message to investors is a compelling invitation to ‘Don't Miss the Bus on the Odisha Growth Story’.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
PharmaTech_LabTech_Expo_2025
AUTOMA+_2025
Ana_Lab_India_2026
PharmaCore_India_2026
×
                                                                                                                               
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram